Citro

HIV Pharm | ID/ASP-trained | Health Equity, HIV, STI, OIs, Public Health | He/Him 🏳️‍🌈🇲🇽🇺🇸| Views are my own | BCPS, BCIDP, AAHIVP #vaccineswork

[Citro @CitroGoesRetro]

Submitted my very first CAB/RPV PA request for PWH viremia and it just got approved 🥹🥳💪🏽 thanks Ward 86 @UCSF_HIVIDGM for publishing your data and advocating for people who are not able to take oral ART options

[Alí Sebastian Meza @AliSMV7]

🔺State-of-the-Art Review: Infections in Patients With Cerebrospinal Fluid Shunts

https://t.co/Se9JYqRi34

[Alí Sebastian Meza @AliSMV7]

🔺 Antiretroviral Therapy (NEJM 2026)

https://t.co/bFHcScjfb5

[Paul Sax @PaulSaxMD]

It includes of course both the traditional and "reverse" algorithms, in all their glory. Question: how can something called a "reverse algorithm" be anything but confusing?
2/5
https://t.co/2e0b9RbwIy

[Paul Sax @PaulSaxMD]

One of the interesting things about a long career in a specialty is seeing the arc of different diseases. C. diff is clearly worse (and much more common) than when I first started practicing, but not nearly as bad as it was in the late 2000s/early 2010s. Good summary here!

[1-min ID consult @1min_IDconsult]

【Reversed halo sign】
Please broaden your differentials beyond Mucormycosis!

#IDMedEd #IDFellow

[1-min ID consult @1min_IDconsult]

【The 5 Ds of outpatient antibiotic stewardship for UTI】
Let's review 5Ds model of stewardship for UTI
・Diagnosis
・Drug
・Dose
・Duration
・De-escalation

Level: Basic

#IDMedEd #IDFellow #MedEd #IMResident

[Paul Sax @PaulSaxMD]

Thanks for the feedback on Part 1 of the "Syphilis Testing is Terrible" post.
Make sure you subscribe to @NEJM @NEJMClinician so you can get the scintillating Part 2! (More terribleness, more jokes.) https://t.co/gu52s6UvNB

[Alí Sebastian Meza @AliSMV7]

🔺IDSA/ESCMID 2026 Guidelines on Staphylococcus aureus Bacteremia

https://t.co/i89qCDCiMy

[Alí Sebastian Meza @AliSMV7]

Hepatitis B in pregnancy and breastfeeding: Current approaches to prophylaxis and treatment

https://t.co/klkSsRSQCb

[Alí Sebastian Meza @AliSMV7]

Mechanisms of HIV-1 assembly, release and maturation

https://t.co/b8KKTnDrVu

[YO_ID @YO_ID_0722]

The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025

@TheTxIDjournal

https://t.co/bHKg4iSEAZ

[YO_ID @YO_ID_0722]

New Perspectives on Antimicrobial Agents: Fosmanogepix

@ASMicrobiology

https://t.co/LkMsjB4zDH

[Brad Spellberg @BradSpellberg]

@spazioguy @ABsteward @MoarSahitoPTI Im glad you asked! Multiple points here...

First, the evidence supporting a 10 day course of abx therapy is the number of metacarpal bones in the hominid hand. The world would have a lot less abx resistance if we had instead evolved as 3 toed sloths.
https://t.co/eGwnRJhUe3

[1-min ID consult @1min_IDconsult]

【Voriconazole: Ocular and neurological effects】

Frequent visual disturbance/hallucination should be fully explained before starting voriconazole!

Level: Intermediate to Advanced

#IDMedEd #IDFellow #TxID

[Sébastien Poulin @sebpoule]

Important #HIV work by @SimonettiFR and team.
Here's a post by Dr Simonetti on LinkedIn👇
#IDXposts
________________________________________

🦀Time to celebrate🦀.

Our study on #HIV non-suppressible viremia despite effective ART has been published in Nature Portfolio (Nat Comm).

We studied ~50 PWH on ART with detectable viremia despite no drug resistance and optimal adherence to investigate the frequency of defective proviruses contributing to HIV in plasma.

Three take home messages:

➡️NSV during long-term ART is most likely caused by 5'Leader defective virus released from infected clones, extending previous work from our group and others.

➡️We developed a digital PCR assay allowing to easily Capture 5'Leader Anomalies Without Sequencing (🦀CLAWS🦀). CLAWS is a "drop-off" dPCR assay that can distinguish intact from mutated or deleted Major Splicing Donor (MSD) sequences, where 5'Leader defects converge.

➡️We observed a progressive increase in 5'L-defective RNA in plasma from 1 month on ART (~1%) to long-term ART (~95%), suggesting differential selective pressure for 5'L-defective proviruses.

You can find the paper here https://t.co/w11cQCpQn9

We hope this study will improve the care of people with HIV with detectable viremia on ART and provide a new tool to study HIV persistence.

This was an incredible collaboration between Johns Hopkins Division of Infectious Diseases, University of Toronto, NIH, and Aarhus University.

Thanks to the Hopkins CFAR, the Ontario HIV Treatment Network and the W.W. Smith Charitable Trust for funding this study.

[YO_ID @YO_ID_0722]

Bridging the Gap Between General and Transplant Infectious Disease Practice

@TheTxIDjournal

https://t.co/eqStyNWF13

[Takahiro Matsuo (Taka), MD @TakaMatsuo_ID]

【The 2026 FIFA World Cup: Communicable disease risks and advice for visitors to Canada, the United States, and Mexico】Travel Med Infect Dis. 2026 May 28

👉Important review on communicable infectious diseases risk!
🇺🇸🇨🇦🇲🇽⚽️🏆

https://t.co/EvyE9BlXkK

#IDMedEd #IDFellow #IMResident

[Paul Sax @PaulSaxMD]

Three really interesting papers, just up on @CIDJournal @IDSAInfo https://t.co/cmqO4DpTHV

[Brad Spellberg @BradSpellberg]

@PulmCrit I think we can rely on 2 complementary principles. 1) use fewer abx of all types to reduce resistance; 2) if you have to use an abx, try not to use ones that clinically treat nosocomial GNB unless necessary. Those principles are not in opposition.

[YO_ID @YO_ID_0722]

Invasive Fusariosis—Time to Break the Mold

@TheTxIDjournal
https://t.co/nYR8Gzfq77